The NSW Government pays patient co-payments for Section 100 (s100) drugs and medicines to help ease the financial burden for people with cancer and other chronic conditions.

s100 co-payments assist people living with cancer, as well as those with conditions such as HIV, patients with organ and tissue transplants, schizophrenia, hepatitis, Crohn’s disease, ulcerative colitis, cystic fibrosis, psoriatic and rheumatoid arthritis, and severe allergic asthma and rare diseases, particularly those affecting children, including juvenile idiopathic arthritis.

Eligibility criteria

  • NSW residents who are patients of:
    • NSW public hospitals
    • authorised community prescribers in NSW
  • Patient prescriptions under Section 100 of the National Health Act 1953 for:
    • s100 Highly Specialised Drugs
    • s100 injectable and infusible chemotherapy medicines.
  • Prescriptions filled through NSW:
    • public hospitals
    • community pharmacies
    • pharmacies used by NSW public hospital oncology services.

Prescribers accredited in NSW for HIV and Hepatitis B medicines are listed on the Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine website. For clozapine, prescribers and patients must meet the PBS eligibility requirements.

The co-payment paid by the NSW Government also counts towards the patient safety net.

Co-payments for patients accessing care in the private sector in NSW remain the same.

Medicine classifications

The Commonwealth Government is responsible for listing medicines on the schedules under the Pharmaceutical Benefits Scheme (PBS). Refer to the PBS website to check the status of a medicine, as the list may change over time.

Evaluation of the NSW s100 Co-payment Initiative

In 2022 the NSW Ministry of Health completed an evaluation of the s100 Co-payment Initiative. The aim was to assess the implementation of the s100 policy from 2016 to 2021 and the extent to which the policy has contributed to improved outcomes.

Using insights and feedback from a broad range of stakeholders, the evaluation showed the initiative has eased the financial burden for patients and awareness of the initiative has increased over time. The initiative has saved NSW patients with cancer and other chronic conditions $43.5 million in s100 medication co-payments over five years.

Please email for a copy of the summary report.

Further information

Current as at: Thursday 8 September 2022
Contact page owner: Strategic Reform and Planning